![]() ![]() Go Solutions has a proven successful track record in developing customized solutions for multibillion-dollars enterprises in the area of operations excellence, employees development & capacity building and transforming cultures. ![]() He launched his training & consultancy company “Go Solutions International” in 2008 which offers customized trainings, consultancy, team buildings and coaching solutions for enterprises and individuals in Africa and MENA Region. Ahmed is specialized in helping people transforming their lives, find their passions, overcome their fears and take control of their lives. "We strongly believe that the availability of early-stage capital coupled with world class research and a strong cluster of early-stage biotech firms provides Canada with all the ingredients to build a robust and vibrant healthcare sector.Is an Entrepreneur, Trainer, Coach, Business Excellence Consultant and AuthorĪhmed throughout his career has successfully coached and trained thousands of people, employees and executives in multinationals all over the world in more than 20 countries over 4 continents in many industries. " BDC Capital is pleased to serve as an anchor LP in the first close of CTI Life Sciences Fund III and support an experienced fund manager who is helping to mentor the next generation of Canadian life science entrepreneurs," said Alison Nankivell, Vice President of Fund Investments, BDC Capital. Our 15-year presence in CTI allows us to support promising Québec companies in life sciences, a key growing industry for the Québec economy," said Kim Thomassin, Executive Vice-President and Head of Investments in Québec and Stewardship Investing at CDPQ. " CDPQ is happy to repeat its involvement with this third fund. ![]() In cooperation with our financial ecosystem partners, we are fulfilling our mission by propelling promising businesses that contribute to the development of an industry that is strategically important for the Québec economy," stated Guy LeBlanc, President and CEO of Investissement Québec. "We are very proud to reiterate our confidence in CTI by participating in the creation of their third major fund dedicated to life sciences. "We're happy to see our savers benefit from the profitability of these investments and that society as a whole is benefiting from the medical advances and the promise of innovative treatments developed by the companies supported by CTI." Béïque, President and CEO of Fonds de solidarité FTQ. "With resounding successes like Enobia Pharma, Zymeworks and GlyPharma, the CTI team has repeatedly demonstrated its ability to invest in the most promising life science companies and help them reach a high level of maturity," said Janie C. And in doing so, CTI LSF looks to make a significant impact on not only the success of those companies, but on the broader provincial and national life sciences industry." "Through CTI LSF III, we seek to further make our mark as a key life sciences investor, supporting highly differentiated and scalable ideas, that we will chaperone forward to significant growth. "Never has the life sciences industry been more critical to the health of both people and economies around the world and as a result, we are seeing a real renaissance in investments in the space", said newly appointed Managing Partner, Youssef Bennani, PhD, MBA, ICD.D at CTI. Its primary focus of investment will remain in Canada where approximately two thirds of the investments will be located, with the remainder in the U.S. CTI LSF will invest from the initial stages of creating new companies to more advanced-clinical-stage organizations.ĬTI LSF III will continue to invest predominantly in biotherapeutics and opportunistically in medical technologies and healthcare IT. The investment strategy for CTI LSF III Fund revolves around the "Inception-2-Inflection" concept. Montreal-based CTI Life Sciences has built a well-respected reputation and track record as a critical and successful investor amongst Canada's life sciences sector. Previously, BDC Capital has invested in CTI LSF II via the Venture Capital Action Plan (VCAP) High Performing Funds program on behalf of the Government of Canada. BDC Capital's Fund Investments team is joining in the first close of CTI LSF III alongside existing LPs. MONTREAL, /CNW Telbec/ - CTI Life Sciences Fund announced today the first closing of its third venture capital fund ("CTI LSF III"), with $100M CDN of capital now available for investment. The new fund includes reaffirmed support from CTI's existing investors, the Fonds de solidarité FTQ, Caisse de dépôt et placement du Québec (CDPQ), Investissement Québec (IQ) and Teralys Capital. ![]()
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |